| Decision | Consent granted Section 13(1)(c) Overseas Investment Act 2005 |
|---|---|
| Decision Maker | Overseas Investment Office |
| Decision Date | 29 April 2020 |
| Pathway | Significant Business Asset |
| Investment | An overseas investment in significant business assets, being the Applicant’s acquisition of the Vendor’s animal health business and assets, which has a value of greater than $100 million. |
| Asset Value | Approximately $267,243,000 (being the value implied by the global transaction value) |
| Applicant | Elanco Animal Health, Inc United States of America (93.0%) United Kingdom (3.0%) France (2.0%) Switzerland (1.0%) Various (1.0%) |
| Vendor | Bayer AG United States of America and Canada (30.2%) German (20.2%) United Kingdom and Ireland (14.2%) Various (35.4%) |
| Background | The Applicant is a global animal health company that innovates, develops, manufactures, and markets products for companion and production animals. The Applicant has applied for consent to purchase the Vendor’s animal health business and assets in New Zealand, as part of the Applicant's purchase of the Vendor's global animal health business. The Applicant intends to continue the operations of the animal health business and assets in New Zealand in the ordinary course. The Applicant has satisfied the OIO that the individuals who will control the investment have the relevant business experience and acumen and are of good character. The Applicant has also demonstrated financial commitment to the investment. |
| More information | Glenn Shewan Bell Gully PO Box 4199 Auckland 1140 |